Last reviewed · How we verify
GD2-SADA:177Lu-DOTA Complex — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GD2-SADA:177Lu-DOTA Complex (GD2-SADA:177Lu-DOTA Complex) — Y-mAbs Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GD2-SADA:177Lu-DOTA Complex TARGET | GD2-SADA:177Lu-DOTA Complex | Y-mAbs Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GD2-SADA:177Lu-DOTA Complex CI watch — RSS
- GD2-SADA:177Lu-DOTA Complex CI watch — Atom
- GD2-SADA:177Lu-DOTA Complex CI watch — JSON
- GD2-SADA:177Lu-DOTA Complex alone — RSS
Cite this brief
Drug Landscape (2026). GD2-SADA:177Lu-DOTA Complex — Competitive Intelligence Brief. https://druglandscape.com/ci/gd2-sada-177lu-dota-complex. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing